Celadon Pharmaceuticals

What it is

Celadon Pharmaceuticals plc is a UK pharmaceutical company focused on cultivating and developing cannabis-based medicines. It is listed on the London Stock Exchange's AIM market under the ticker CEL ^[1]. The company operates a Home Office–licensed cultivation and production facility in the Midlands, which it has publicly described as one of the few UK sites licensed to grow high-THC cannabis at commercial scale ^[1][2]. Its stated business model combines (a) producing GMP-grade medical cannabis flower and extracts for the UK private prescription market and (b) running clinical research aimed at registering a cannabis-based medicine for chronic pain ^[2].

Ownership and structure

Celadon Pharmaceuticals plc is the parent company; it trades on AIM following its 2022 admission ^[1]. Subsidiaries have included LeafCann Research (clinical/research activities) and the cultivation operation in Birmingham ^[1]. Like other small-cap AIM pharma firms, ownership is a mix of founders, directors, and institutional and retail shareholders; current substantial holdings should be checked in the company's most recent annual report or regulatory filings rather than relied on from secondary sources No data.

Market and category focus

Celadon sits in two overlapping categories:

• Domestic medical cannabis supply. Medical cannabis has been legal on prescription in the UK since November 2018, but the overwhelming majority of product dispensed through UK private clinics is imported from Canada, the Netherlands, Portugal, Australia, or Israel ^[3]. Celadon's pitch is import substitution: UK-grown, GMP-produced flower and extracts sold into the same private prescription market.
• Pharmaceutical development. The company has run a clinical trial of a cannabis-based medicine in chronic non-cancer pain, with the longer-term goal of producing a registered medicine rather than only an unlicensed 'special' ^[2]. Outcomes and regulatory status of that programme should be checked in current filings before being treated as established. Weak / limited

Notable products and services

Celadon does not sell cannabis direct to consumers. Products reach patients only via UK-registered prescribers and specialist pharmacies under the Medical Cannabis in the UK framework ^[3]. Publicly described product activity has included:

• GMP-grade dried cannabis flower cultivars grown at the Birmingham facility.
• Cannabis-based investigational medicinal product(s) used in its chronic pain trial ^[2].

This profile does not recommend any Celadon product. Specific cultivar names, cannabinoid contents, and availability change frequently; the canonical source is the company itself and the dispensing pharmacy at the time of prescription.

Reputation and coverage

Celadon has received UK business and trade press coverage as one of the early domestic cultivators to receive Home Office licensing for high-THC cannabis ^[1][2]. That licensing is real and verifiable through company announcements and Home Office statements, and it is genuinely uncommon in the UK context. Beyond that, claims about being 'the only' or 'the first' UK grower vary by definition (low-THC hemp vs high-THC cannabis; research vs commercial licence) and should be read carefully Disputed. Awards and rankings in the cannabis sector are largely industry-run and do not constitute independent quality assessment.

Controversies and regulatory issues

As of the last check for this profile, there are no widely reported regulatory enforcement actions against Celadon by the MHRA, Home Office, or financial regulators that we can verify No data. The company has, however, like many AIM-listed small-caps in cannabis and biotech, experienced significant share price volatility, multiple fundraises, and shifting commercial timelines since its 2022 listing ^[1]. Investors and patients evaluating the brand should distinguish between operational milestones (licences granted, harvests, prescriptions filled, trial readouts) and forward-looking statements in investor presentations.

Availability and legal market notes

In the UK, cannabis remains a Schedule 2 controlled drug; it can only be prescribed by specialist doctors on the GMC Specialist Register, and almost all prescriptions are private rather than NHS ^[3]. Patients cannot buy Celadon products directly. Outside the UK, Celadon has at times discussed export ambitions to other regulated medical markets; any current export activity should be verified against the company's latest RNS announcements rather than older press coverage Weak / limited.

What to verify before relying on brand claims

Before treating any Celadon-related claim as fact, check:

1. Licensing status. Home Office cultivation licences and MHRA manufacturing authorisations are time-limited and site-specific.
2. Listing status. AIM listings can be suspended, cancelled, or restructured; confirm CEL's current trading status on the London Stock Exchange.
3. Clinical trial status. Trial registrations (e.g. on ISRCTN or ClinicalTrials.gov) and published results, not press releases, are the authoritative record.
4. Product availability. Whether a specific cultivar or extract is in stock at UK specialist pharmacies changes month to month.
5. Financial claims. Revenue, prescription numbers, and patient counts cited in marketing should be cross-checked against audited annual reports.

Profile last checked: 2024.

Sources

How this page was made